EbeneNews – GB – Diginex lists and starts trading on Nasdaq


    HONG KONG, Oct. 2, 2020 / PRNewswire / – Diginex Limited (« Diginex » or the « Company »), a digital asset financial services company, today announced that it has completed its business combination transaction (the « Transaction ») with 8i Enterprises Acquisition Corp (Nasdaq: JFK) (« 8i »), a Special Purpose Acquisition Company (« SPAC ») The transaction, which was approved at an extraordinary shareholders’ meeting on September 15, 2020, creates the first company listed on the Nasdaq with a cryptocurrency exchange

    Diginex Limited will trade on the Nasdaq under the symbol « EQOS » where it will provide investors with the opportunity to participate in the growth of digital assets The company’s warrants will trade under the symbol « EQOSW »

    Approximately US $ 50 million has been raised, including both the private increase in Diginex achieved before listing and the remaining cash in the PSPC This will strengthen the company’s balance sheet and enable it to achieve its vision of building an ecosystem of digital assets that delivers innovative products and services that are compliant, fair and reliable

    Richard Byworth, CEO of Diginex, said: “This is a watershed moment for Diginex and the cryptocurrency industry with the listing of the very first company with a crypto exchange on Nasdaq This also represents the first opportunity for anyone trading in the US financial markets to buy directly into the equity of a digital asset ecosystem and opens the door for financial institutions to participate in the huge opportunity that digital assets present »

    « Diginex offers a unique set of innovative products and institutional grade infrastructure Our EQUOSio exchange is regulatory driven and will offer features such as segregation of duties, portfolio margin and cross collateralization, which are typically not not available on the crypto exchange market »

    « While EQUOSio is the heart of our ecosystem, we are also the first company to have an integrated offering comprising a regulated asset manager, cold and hot preservation solutions, advice on capital markets as well as a multi-media trading platform that connects to some of the world’s leading providers of trading technology « 

    Chi-Won Yoon, President of Diginex, said: « We are delighted to have reached this milestone for the industry and Diginex The Nasdaq list demonstrates our commitment to bring transparency and accountability to the digital asset industry. to investors greater assurance on the growth and long-term viability of this asset class « 

    Chardan acted as financial advisor and Loeb and Loeb LLP acted as legal advisor to 8i Winston & Strawn LLP acted as legal advisor to Diginex

    Diginex is a digital asset financial services company focused on delivering a cryptocurrency and digital asset ecosystem offering innovative compliant, fair and reliable products and services The group understands the exchange EQUOSio cryptocurrency as well as an over-the-counter trading platform It also offers a front-to-back integrated trading platform Diginex Access, a securitization advisory service Diginex Capital, the main hot and cold custodian market, Digivault and the Bletchley Park Asset Management fund activity For more information, visit: https: // wwwdiginexcom /

    Follow Diginex on social media on Twitter @DiginexGlobal, on Facebook @DiginexGlobal and on LinkedIn Follow EQUOSio on social media on Twitter @EQUOS_io and on LinkedIn

    This press release contains forward-looking statements that involve risks and uncertainties Forward-looking statements are statements that are not historical facts These forward-looking statements are subject to risks and uncertainties, which could cause actual results differ from forward-looking statements. These risks and uncertainties include, but are not limited to, the factors described in the section entitled “Risk Factors” of Diginex’s registration statement on Form F-4 filed jointly by Diginex and 8i regarding the business combination (the “Form F-4”) Significant factors, among others, that may affect actual results or results include: the inability to recognize the expected benefits of the proposed transaction, which could be affected, among other things, by the amount of cash available following possible shareholder buybacks res of 8i; the ability to meet Nasdaq listing standards following completion of the proposed transaction; and the costs associated with the proposed transaction Important factors that could cause the actual results or results of the combined company to differ materially from those discussed in the forward-looking statements include: Diginex’s limited operating history and historical net losses; The ability of Diginex to manage growth; Diginex’s ability to execute its business plan; Diginex’s estimates of the size of markets for its products; the rate and degree of market acceptance of Diginex products; Diginex’s ability to identify and integrate acquisitions; potential litigation involving Diginex or the validity or enforceability of Diginex’s intellectual property; general economic and market conditions impacting demand for Diginex products and services; and the other risks and uncertainties referred to in 8i’s prospectus filed as part of its initial public offering and in the proxy circular to be filed relating to the business combination

    Diginex expressly disclaims any obligation or commitment to publicly post any update or revision to any forward-looking statement contained herein to reflect any change in Diginex’s expectations in this regard or any change in events, conditions or circumstances on which a statement is based on

    ‹Hotels, pubs and restaurants across Australia are holding back bettors, but wasting time typing Tracking and tracing regulations require establishments to record information about each customer, resulting in delays for many customers, while others deliberately falsify their data

    To address these issues, Austrian tech company Anyline released software to scan Australian driver’s licenses and passports on any smartphone This technology provides hospitality staff with a fast, contactless way to collect the data needed by each guest at check-in Unlike QR code systems, customers do not need to enter their information themselves. which means incorrect data cannot be entered

    The hospitality industry is caught between a rock and a tough place: fighting every day to protect jobs and welcoming customers back while doing everything in their power to ensure safety, the CEO said from Anyline, Lukas Kinigadner But when staff have a quick, contactless way to check in each guest with their own phone, queues can be cut, no one can enter false data, and to ensure that the best records are kept for contact tracing

    The company, founded in 2013, is known to offer its technology free of charge to emergency and humanitarian services as the COVID-19 pandemic has taken hold, and is currently used by the United Nations World Food Program (WFP ) for the distribution of aid Their technology has also been incorporated into the LEAD Horizon COVID-19 home test kits which are widely sold in Austria, providing results within 24 hours.

    Anyline has established itself as a market leader in mobile text recognition Using the latest and most innovative artificial intelligence approaches, Anyline enables any mobile device to process written characters in real time, even offline It is not only more accurate than manual data entry, but also works 20 times faster

    Anyline is the trusted choice for identity scanning for large corporations and national governments and is used by over 100,000 police officers around the world in their daily work In Austria, it has also been integrated into a ˜Digital Office app which can be used by every Austrian resident to perform municipal tasks such as home registrations

    The same technology will also soon be integrated to scan the new ˜E-Vaccination passports, which will significantly improve the vaccination registration process With the latest version of Anyline, the verification of identifiers in the EU, America North and Australia is already in active use with extended coverage scheduled regularly over the coming months

    With over 300 active client companies producing over a million mobile scans every day, it’s clear that the future of data collection is automation and we’re proud to be leading the change worldwide

    Frontier Communications Corporation (OTC: FTRCQ) (Frontier Communications) announced today that it has priced its previously announced offering of $ 1.150 billion in aggregate principal amount of senior secured notes due 2027 (the Senior Secured Notes) in Private Transaction The Senior Secured Notes will bear interest at 5875% per annum and will be sold at a price equal to 100% of the principal thereof Settlement of the Senior Secured Notes Rank is expected to occur on or around October 8, 2020, subject to customary closing conditions

    Frontier Communications intends to use the proceeds of the Offering, as well as the proceeds of a new $ 500 million senior term loan facility (the New Term Loan Facility) and the cash on hand to (i) repay in full the USD650 billion principal balance of the existing preparation 8,000% senior secured notes due 2027 and (ii) pay interest, fees and related expenses incurred in this regard. Senior Secured Notes is subject to market and other conditions The New Term Loan Facility will be at a price equal to 9850% of its face value and will bear interest at an equal rate, at the option of Frontier Communications , either LIBOR plus 475% or base rate plus 375%, with a 100% LIBOR floor

    As previously reported, on April 14, 2020, Frontier Communications and certain of its subsidiaries filed willful proceedings (Chapter 11 cases) under Chapter 11 of the United States Bankruptcy Code (Bankruptcy Code) before the United States Bankruptcy Court for the Southern District of New York (Bankruptcy Court) On August 21, 2020, the Bankruptcy Court upheld Frontier Communications’ reorganization plan (the plan) for the resolution of outstanding claims and interests against Frontier Communications pursuant to Article 1121 (a) of the Bankruptcy Code Implementation of the plan depends on a number of conditions typical of similar reorganizations, including obtaining regulatory approval On September 17, 2020, the bankruptcy court issued a final order allowing Frontier Communications to obtain a debtor financing in possession, including approval of this offer

    This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor any sale of any securities referred to in this press release in any jurisdiction in which such an offer, solicitation or sale would be illegal

    All offers of Senior Secured Notes have been made only by way of private offering memorandum to persons reasonably considered to be qualified institutional buyers under Rule 144A under the Securities Act of 1933, as amended (the Securities Act) and to non-US persons outside the United States under Regulation S of the Securities Act The Senior Secured Notes have not been registered under the Securities Act or any laws on securities of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements

    Frontier Communications Corporation (OTC: FTRCQ) provides a variety of services to residential and commercial customers over its fiber optic and copper networks in 25 states, including video, high-speed Internet, advanced voice and digital protection solutions Frontier Secure Frontier Business „¢ offers communication solutions to small, medium and business

    This press release contains forward-looking statements relating to future events Forward-looking statements relate to the future business, financial performance and expected financial condition of Frontier Communications and contain words such as “expect”, “anticipate” , « Intend », « plan », « believe », « seek », « see, » « May », « will », « would » or « target » Forward-looking statements, by their nature, deal with matters which are, to varying degrees, uncertain To Frontier Communications, the specific uncertainties that could cause actual results to differ materially from those expressed in these forward-looking statements include: our ability to continue as a going concern; our ability to complete the restructuring of our existing debt, existing holdings and certain other obligations (the restructuring), and to emerge from Chapter 11 cases in bankruptcy court, including by meeting both the conditions the plan and the conditions and milestones in the restructuring aid agreement; our ability to improve our liquidity and long-term capital structure and to meet our debt service obligations through restructuring and the potential negative effects of Chapter 11 cases on our liquidity and results of exploitation; our ability to maintain relationships with suppliers, customers, employees and other third parties as a result of the restructuring and Chapter 11 cases; the effects of the restructuring and the Chapter 11 affairs on us and the interests of various constituents; the risks and uncertainties associated with the Restructuring, including our ability to meet the preconditions for the effectiveness of the Restructuring and to complete it in accordance with the Plan in the Cases of Chapter 11; our ability to comply with the restrictions that should be imposed by debtor in possession and exit financing covenants; the length of time we will operate under Chapter 11 protection and the continued availability of working capital during the life of Chapter 11 business; risks associated with third party claims in Chapter 11 cases, which may interfere with the Company’s ability to complete the restructuring; increased administrative and legal costs associated with the Chapter 11 process; declining revenues from our voice, switched and non-switched access, and video and data services that we cannot stabilize or offset by increases in revenues from other products and services; decreases in adjusted EBITDA from historical levels that we cannot offset by potential improvements in EBITDA; our ability to successfully implement strategic initiatives, including opportunities to increase revenue and achieve productivity improvements; our ability to effectively manage our business, operating expenses, capital expenditures, debt service requirements and cash paid for income taxes and cash; competition from cable, wireless and wireline, satellite and larger companies, and the risk that we may not respond in a timely or cost effective manner; our ability to successfully adapt to changes in the communications industry, including the effects of technological change and competition on our capital expenditures, products and service offerings; risks associated with disruption of our networks, infrastructure and information technology which results in the loss of customers and / or the occurrence of additional expenses; the impact of possible information technology or data security breaches or other cyber attacks or other disruptions; our ability to retain or attract new customers and to maintain relationships with customers, employees or suppliers; our ability to secure, continue to use or renew intellectual property and other licenses used in our business; changes to our board of directors and management team upon exiting or anticipating bankruptcy, and in our ability to hire or retain key personnel; our ability to dispose of certain assets or groups of assets on terms that are of interest to us or not at all; the effects of changes in the availability of federal and state universal service funding or other subsidies to us and our competitors and our ability to secure federal and state universal service funding and other subsidies in the future; our ability to meet our Connect America Fund (CAF) Phase II obligations and the risk of penalties or obligation to return certain CAF Phase II funds; our ability to defend against litigation and potentially adverse outcomes from ongoing and future litigation; our ability to comply with applicable federal and state consumer protection requirements; the effects of state regulatory requirements that could limit our ability to transfer liquidity between our subsidiaries or dividend funds to the parent company; the effects of government laws and regulations on our business, including costs, disruptions, possible limitations on operational flexibility and changes in the competitive landscape resulting from such laws or regulations; the impact of regulatory, investigative and legal procedures and legal compliance risks; government infrastructure projects (such as road construction) that impact our capital spending; continued reductions in dial-up revenues due to regulation, competition or technology substitutions; our ability to effectively manage quality of service in the states in which we operate and to meet mandatory quality of service parameters; the effects of changes in income tax rates, tax laws, regulations or rulings, or federal or state tax assessments, including the risk that such changes may benefit our competitors more than us, as well as possible future decreases in the value of our deferred tax assets; the effects of changes in accounting policies or practices, including any future impairment charges on our intangible assets or additional losses on assets held for sale; the effects of increased medical, retirement and post-employment expenses; our ability to successfully renegotiate union contracts; changes in pension plan assumptions, interest rates, discount rates, regulatory rules and / or the value of our pension plan assets, which could require us to make increased contributions to the plan retirement in 2020 and beyond; adverse changes in economic, political and market conditions in the regions we serve, the US and globally, including, but not limited to, changes resulting from epidemics, pandemics and disease outbreaks of contagious diseases, including the global coronavirus pandemic, or other adverse public health developments; and the potential negative impacts of the COVID-19 pandemic on our business and operations, including potential disruptions to the work of our employees resulting from health and safety measures such as social distancing and remote working, our ability to effectively manage the increase in demand on our network, our ability to maintain relationships with our current or potential customers and suppliers, as well as their ability to operate within current or proposed agreements with us, and stress on our supply chain Forward-looking statements are also subject to the risk factors and cautionary language described from time to time in the Company’s reports to the US Securities and Exchange Commission, including those set out in the latest Company Annual Report on Form 10-K and any related updates in the Company’s Quarterly Reports on the e Form 10-Q and the current reports on Form 8-K These risks and uncertainties may cause actual future results to differ materially from those expressed in these forward-looking statements Frontier Communications has no obligation to update or revise these statements prospective and does not undertake to do so

    As the European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO (Kidney Disease: Improving Global Outcomes) 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD) The new guideline recommends the use of the sodium-glucose co-transporter-2 inhibitor class (SGLT2i), which includes canagliflozin, as a first-line treatment option alongside metformin for burden of hyperglycemia in patients with type 2 diabetes mellitus (T2DM), CKD and eGFR ‰ ¥ 30 ml / min / 173 m21

    This new guideline includes data from CV Outcome Trials (CVOTs) for SGLT2is that demonstrate significant cardioprotective effects and possible renal protective effects across the classroom This includes data on positive CV results for canagliflozin 2, empagliflozin and dapagliflozin, and results for CRF from the canagliflozin clinical trial CREDENCE3 The guideline also emphasizes that if renal events were outcomes secondary in most CVOTs, CREDENCE was the first randomized controlled trial specifically designed for primary renal outcomes in patients with exclusively albuminuric CRF3

    The CREDENCE trial is the first study dedicated to renal results in patients with DKD and T2DM The study recruited 4,401 subjects with an eGFR of 30 to 300 to 5000 mg / g) It is important to note that all patients were treated within a standard care setting for DKD, including a maximum tolerated dose of an ACE inhibitor or an ACE inhibitor. ARB results showed that canagliflozin demonstrated a 30% reduction, compared with placebo, in the risk of the composite primary endpoint, including end-stage renal disease (ESRD), doubling of serum creatinine, and renal or cardiovascular death ( CV), with event rates of 432 versus 612 per 1000 patient-years, respectively (Hazard Ratio [HR]: 070; 95% Confidence Interval [CI]: 057 to 084; p <00001) 5

    Canagliflozin received approval from the European Commission (EC) in July this year, to expand its treatment of the T2DM indication in Europe to treat diabetic renal failure (DKD) in DT26 C patients is currently the only SGLT2i labeled to treat DKD in TD2M patients

    KDIGO’s recommendations are based on evidence from recent clinical trials.These trials include CREDENCE, which has shown that canaglifozin reduces the risk of deteriorating kidney function and associated cardiovascular complications in patients with both type 2 diabetes and chronic kidney disease CREDENCE is one of the reasons SGLT2 inhibitors were given a prominent place in the management of diabetes in the guideline, said Professor David Wheeler, professor of renal medicine at University College London and consultant nephrologist honorary at the Royal Free NHS Foundation Trust, London, United Kingdom

    Around 59 million adults in Europe are currently living with diabetes and around 90% of them have T2DM This figure is expected to increase to 68 million by 20457 If left untreated, people with T2DM are at greater risk of developing serious health complications, such as CRF, heart failure (HF), and cardiovascular disease, which are the most common cause of death among them8 It is estimated that around 40% of people with T2DM will develop CKD, 4 effective therapies must be sought early to stop the progression of the disease1

    People with type 2 diabetes and chronic kidney disease are at greater risk of cardiovascular disease and progression to end-stage kidney disease, so it is essential that doctors have clear guidelines that recommend appropriate therapies for help prevent these risks, said Dr Vinicius Gomes de Lima, Head of European Medical Affairs, Mundipharma

    About the KDIGO1 Guide The first KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guide for the Management of Diabetes in Chronic Kidney Disease has been posted at https: // kdigoorg / wp-content / uploads / 2018/03 / KDIGO-Diabetes-in-CKD-GLpdf

    About Invokana (canagliflozin) Canagliflozin is a once-daily oral medicine that belongs to a class of drugs called sodium glucose 2 co-transporter inhibitors (SGLT2) SGLT2 inhibitors work by inhibiting co -carrier of SGLT2, which promotes the excretion of glucose through urine, and thus helps lower blood sugar in adults with T2DM5

    Canagliflozin was approved in the European Union by the European Commission in November 2013.It is indicated for the treatment of adults with insufficiently controlled T2DM as a supplement to diet and exercise, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications and as an adjunct to other medicines for the treatment of diabetes5

    The recommended starting dose of canagliflozin is 100 mg once daily in adults with an eGFR of ‰ ¥ 60 mL / min / 173 m2 and may be increased to 300 mg once daily if tighter blood sugar control is required For patients with an eGFR of 45 to <60 mL / min / 173 m2 the initial dose is limited to 100 mg once daily, if additional glycemic control is required the addition of other antihyperglycemic agents should be considered In patients with an eGFR of 30 to <45 mL / min / 173 m2 with a urine albumin / creatinine ratio ˃ 300 mg / g, the initial dose is limited to 100 mg once daily, if additional glycemic control is required , the addition of other antihyperglycemic agents should be considered.Canagliflozin should not be started if eGFR is less than 30 mL / min / 173 m2, but for patients already taking canagliflozin, it should be continued at 100 mg up to '' that a dialysis or a transpl renal antation is necessary5

    About the CANVAS2 Program The CANVAS program (N = 10,142) included the two large cardiovascular trials of canagliflozin, CANVAS and CANVAS-R, and included a pre-defined integrated review of these two studies to assess CV protection potential. canagliflozin in patients with T2DM who had a history of CV disease or at least two CV risk factors The integrated analysis also assessed the effects of canagliflozin on renal and safety outcomes

    Canagliflozin achieved the primary efficacy endpoint of significantly reducing the composite rates of major adverse CV events (MACE) including CV mortality, non-fatal myocardial infarction (MI), or non-fatal stroke (269 vs. 315/1000 patient-years, risk ratio (HR) 086; 95% confidence interval (CI 075-097; P <00001 for non-inferiority; P = 00158 for superiority) compared to placebo plus norm of care, respectively The 3 components of the MACE composite (CV death, non-fatal MI and non-fatal stroke) presented point estimates of the effect suggesting a benefit with canagliflozin

    Adverse events reported in the CANVAS program were generally consistent with the known safety profile of canagliflozin Although an increase in lower limb amputation and bone fractures were observed in the CANVAS program, this signal has not been observed in other long-term clinical trial data involving high-risk patients3

    About the CREDENCE3 clinical trial The CREDENCE study (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) was the first dedicated and fully recruited renal outcome study to assess renal and cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) with sodium glucose 2 co-transporter inhibitor (SGLT2) This was a multicenter, phase III, randomized, double-blind, study based on event, placebo-controlled, parallel group, two-armed, effects of canagliflozin on renal and cardiovascular outcomes in subjects with T2DM and CRF In particular, he compared the efficacy and safety of canagliflozin versus placebo in preventing clinically important renal and cardiovascular outcomes in patients with T2DM and CRF when used in addition to standard care. , including a maximum tolerated daily dose of an angiotensin converting enzyme (ACEi) inhibitor or angiotensin receptor blocker (ARB)

    About the Mundipharma Network Mundipharma is a global network (excluding the United States) of private independent associated companies present in Africa, Asia-Pacific, Europe, Canada, Latin America and the Middle East

    We are committed to bringing patients with severe and debilitating diseases the benefits of new treatment options in areas such as anti-infectives, biosimilars, CNS, diabetes, oncology & supportive care, ophthalmology, pain management, respiratory and consumer care

    For more information by geographic region, please see wwwmundipharmacom (Europe); wwwpurdueca (Canada) and wwwmundipharmacomsg (other markets outside the United States)

    Invokana is a registered trademark of Johnson & Johnson The marketing authorization holder is Janssen-Cilag International NV

    1 KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease Kidney International October 2020; 98 (4S): S1 « S115 Available at https: // kdigoorg / wp-content / uploads / 2018/03 / KDIGO-Diabetes-in-CKD-GLpdf Last consulted in September 2020

    2 Neal B et al Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes The New England Journal of Medicine (2017); 377: 644-657

    3 Perkovic, V et al Canagliflozin and Renal Results in Type 2 Diabetes and Nephrology The New England Journal of Medicine 2019; 380 (24): 2295-2306

    4Alicic R, Rooney M, Tuttle K Diabetic Kidney Disease: Challenges, Progress and Opportunities Clin J Am Soc Nephrol 2017; 12 (12): 2032-45

    6 European Commission June 26, 2020 Decision C (2013) 8171 (final) for Invokana “canagliflozin Available at https: // eceuropaeu / health / documents / community-register / html / h884htm Last consulted in July 2020

    7 IDF Diabetes Atlas, Ninth Edition 2019 Available at: https: // wwwdiabèteorg / en / resources / Last accessed July 2020

    8 Einarson T, Acs A, Ludwig C et al Prevalence of cardiovascular disease in type 2 diabetes: a systematic review of the scientific evidence literature from around the world in 2007-2017 Cardiovasc Diabetol June 8, 2018; 17 (1): 83

    ‹Hotels, pubs and restaurants across Australia are holding back punters, but wasting time typing Track and trace regulations demand

    Frontier Communications Corporation (OTC: FTRCQ) (Frontier Communications) announced today that it has priced its previously announced $ 1.150 billion offering

    As European distributor of Invokana (canagliflozin) and Vokanamet (canagliflozin and metformin), Mundipharma welcomes the publication of the first KDIGO

    The global automotive powder metallurgy components market size is expected to grow by USD 1.06 billion in 2020-2024, growing to

    Schnitzer Steel Industries, Inc (NASDAQ: SCHN) today announced that the company will release financial results for its fourth quarter and

    BMW of North America today announced third quarter 2020 sales results for the BMW and MINI brands in US For

    McLarens, a leading global independent insurance services provider, is pleased to announce the strategic acquisition of CNZ Group Holdings Limited

    BBX Capital, Inc (OTCQX: BBXIA) (PINK: BBXIB) (the Company), which was split by Bluegreen Vacations Holding Corporation (the former BBX

    Lathrop GPM LLP announces that Jasmine Trillos-Decarie joins the firm as first Chief Client Officer after an exhaustive search

    Platform Calgary is pleased to announce the 20 companies participating in the Junction Junction program is a nine-week full-time residency

    Global Banking & Finance Review® is a leading financial portal and print magazine offering news, analysis, opinions, reviews, interviews & Videos from the world of banking, finance, business, trading, technology, investment, brokerage, foreign exchange, Taxation & Legal, Islamic Finance, Assets & Wealth Management
    Copyright © 2010-2020 GBAF Publications Ltd – All rights reserved

    Necessary cookies are absolutely essential for the proper functioning of the site This category only includes cookies that provide basic functionality and security features of the website These cookies do not store any personal information

    NASDAQ, Diginex Limited, cryptocurrency exchange, Bitcoin

    EbeneNews – GB – Diginex lists and starts trading on Nasdaq

    SOURCE: https://www.w24news.com/news/ebenenews-gb-diginex-lists-and-starts-trading-on-nasdaq/?remotepost=364005

    Abonnez-vous à notre chaîne Youtube en cliquant ici

    Vidéo du jour: De la cocaïne retrouvée dans une école maternelle de Seine Saint Denis, deux enfants hospitalisés

    Laisser un commentaire, votre avis compte!